METASTATIC GASTRIC CANCER

This study tests a new combination of drugs (iparomlimab and tuvonralimab, called QL1706) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if the combo can shrink tumors and control the disease…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This early-phase trial tests a new treatment called p95HER2.CAR-TECH2Me for people with advanced HER2-positive cancers (breast, stomach, or endometrial cancer that has spread). The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and at…

This study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…

This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug aims to block a protein (CD73) that helps tumors hide from the immune system. The trial first finds the safest dose alone, then tests it with chemotherapy and an…

This study tests a new drug, SHR2554, combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and helps shrink tumors or slow the dise…

This study tests a mix of immune cells (agenT-797) and three immunotherapy drugs (botensilimab, balstilimab, ramucirumab) plus chemotherapy (paclitaxel) for people with advanced stomach, esophageal, or gastro-esophageal junction cancer that has worsened after one prior treatment.…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This study looks at whether giving the chemotherapy drug paclitaxel over a longer time (2-3 hours) to cancer patients with low muscle mass can make the drug level in their blood similar to patients with normal muscle mass who get the standard 1-hour infusion. About 22 women with …